BioSpace News Archive

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has obtained prequalification certification from the World Health Organization for its typhoid conjugate vaccine, ‘SKYTyphoid®'.

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), as well as foundational preclinical data for BLU-808, an investigational highly selective and potent oral inhibitor of wild-type KIT.

Vir Biotechnology, Inc. announced that management will be participating in the following upcoming investor conferences during the month of March: TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston.

Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for cefepime-taniborbactam.

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”) today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require appropriate treatments.

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) announces an R&D update including positive top-line clinical trial results of a recently completed Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG, and results of a preclinical experiment designed to demonstrate tolimidone’s potential for beta cell proliferation in an in vitro model.

BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.

Jaguar Health, Inc. provided an update regarding the status of its listing with The Nasdaq Stock Market LLC.